Loading...
XKRX
095700
Market cap63mUSD
Jul 10, Last price  
2,415.00KRW
1D
4.55%
1Q
-50.31%
Jan 2017
-94.40%
IPO
-86.24%
Name

Genexine Inc

Chart & Performance

D1W1MN
XKRX:095700 chart
P/E
—
P/S
21.89
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.01%
Rev. gr., 5y
-24.42%
Revenues
4.57b
+55.96%
6,251,652,91032,519,853,39211,351,915,01428,454,503,37112,881,557,48211,303,045,00018,543,495,00036,828,455,00016,139,032,0004,426,627,0002,932,736,0004,573,913,000
Net income
-27.01b
L-57.60%
-2,096,046,609-1,426,677,194-30,932,738,688-19,329,560,416-34,066,759,817-16,509,197,00027,569,725,000-47,726,585,000-55,973,928,000-66,873,518,000-63,705,875,000-27,013,259,000
CFO
-29.58b
L+1,694.72%
1,668,236,620-1,642,633,914-14,099,260,886-26,104,449,145-20,054,235,453-41,571,709,000-22,690,959,000-12,745,360,000-39,799,586,000-38,054,512,000-1,648,409,000-29,584,355,000
Dividend
Mar 15, 20220.3964 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
URL
http://genexine.com/
IPO date
Sep 15, 2009
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT